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Systemic corticosteroids are almost universally used in the treatment of severe acute asthma but the optimum 
length of treatment with corticosteroids following recovery from an acute attack of asthma is not established. 
Thirty-five patients admitted with acute asthma and treated with oral prednisolone 40 mg daily in addition to 
bronchodilator therapy until full recovery, with stable peak expiratory flow recordings (PEF) within 15% of 
their previous best PEF or predicted PEF were studied. They were all discharged home on regular inhaled 
corticosteroids and regular or as required use of bronchodilators and randomized to receive either 
prednisolone 40 mg daily or placebo for the first 14 days. Median PEF values increased from 31% predicted 
on admission to hospital to 71% predicted on discharge from hospital in the active treatment group (19 
patients) and from 32-73% in the placebo group (16 patients). There was no difference between the two groups 
in the median values of the forced expiratory volume in one second, forced vital capacity, total lung capacity 
or diurnal variation in PEF either at the time of discharge from hospital or at 14 and 28 days after discharge 
from hospital. This study suggests that there is no need to reduce prednisolone gradually following recovery 
from an exacerbation of asthma, provided systemic corticosteroid treatment is continued until a satisfactory 
and stable PEF is achieved. 
Introduction 
There is a general agreement about the need to use 
relatively high dose systemic corticosteroid treatment 
in acute asthma. This is usually started at the earliest 
opportunity and continued until symptoms and 
pulmonary function improves to a satisfactory level. 
Although the dose response characteristics of pred- 
nisolone in acute asthma are well documented (1), 
there is little published work on the length of treat- 
ment required following clinical recovery from an 
acute exacerbation of asthma. Advice generally varies 
from continuing corticosteroids for 7-14 days follow- 
ing discharge from hospital with an abrupt cessation 
of corticosteroid treatment or a gradual ‘tailing off 
of treatment (2,3). 
This double-blind placebo controlled study was 
designed to compare an abrupt cessation of pred- 
nisolone treatment with a gradual ‘tailing off of 
treatment in patients admitted with an acute exacer- 
bation of asthma once their asthma had improved 
and remained stable for 48 h in hospital. 
Methods 
Patients aged 1680 years admitted with an acute 
attack of asthma were studied. Treatment of these 
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patients was not standardized except that all patients 
received prednisolone 40 mg a day from the date of 
admission. Those on long term oral corticosteroids 
and those who required ventilatory support during 
the admission were excluded from the study. Patients 
included were required to have achieved at least a 
doubling of their admission peak expiratory flow rate 
(PEF) prior to discharge from hospital and to have 
achieved a PEF at the time of discharge which was 
within 15% of the previous pre-admission best 
recorded PEF values or within 15% of predicted. 
They were also required to have achieved a stable 
PEF over 48 h; this was defined as < 15% variability 
in PEF measured at the same time of day. The study 
was approved by the local medical ethics committee 
and informed consent was obtained from all patients. 
All patients were discharged on inhaled corti- 
costeroid treatment (daily dose range of budesonide 
or beclomethasone was 400-2000 ug) and broncho- 
dilators. They were randomized to receive a 14 day 
course of prednisolone or placebo. The dose of 
prednisolone was reduced by 5 mg every second day. 
An emergency supply of prednisolone was given to 
all patients together with an appropriate self manage- 
ment plan. Patients were asked to keep twice daily 
PEF recordings (taken before inhalers) with a mini- 
Wright peak flow meter. FEV, and FVC were 
‘i’, 1995 W. B. Saunders Company Ltd 
102 hf. Q. F. Hatton et al. 
measured using a dry bellows spirometer (Vitalo- 
graph) and lung volumes were measured using a 
constant volume body plethysmograph (PK Morgan, 
U.K.) on day 1 (day of discharge) and on days 14 
and 28. 
Analysis 
Of the 40 patients entered into the study (21 active 
treatment and 19 placebo), five (two active, three 
placebo) defaulted from the study for social reasons 
and were excluded from the study. Following dis- 
charge from hospital eight patients (five active, three 
placebo) required treatment with prednisolone for an 
exacerbation of asthma; two of these patients in each 
group required treatment in the first 14 days. Because 
exclusion of the results of these eight subjects would 
have introduced bias, non-parametric methods were 
used to compare the active and placebo treated 
groups to enable all subjects recruited to the study 
(excluding social defaulters) to be included in the 
analysis (4,5). Subjects who required prednisolone 
treatment were assumed to have deteriorated and 
allocated worst group values from the time they were 
treated with prednisolone. 
PEF, FEV,, FVC and TLC values were expressed 
as % predicted for analysis and diurnal variation 
in PEF was calculated as amplitude % mean (100 x 
[difference between PEF am and PEF pm]/mean 
PEF). The values obtained at 14 and 28 days (mean 
over 7-14 days and 21-28 days in the case of PEF) 
were compared with the baseline values at discharge 
in each group using Wilcoxon’s rank-sum test to 
determine if there had been a significant change in 
these values following hospital discharge. In addition 
the baseline values obtained on the day of discharge 
from hospital (the mean over the last 2 days before 
discharge in the case of PEF) and the change from 
baseline in these values at 14 and 28 days (mean over 
7-14 days and over 21-28 days in the case of PEF) 
were compared between the two groups by the 
Wilcoxon rank-sum test. 
Results 
Nineteen patients in the active treatment group 
(median age 30 years) and 16 patients in the placebo 
group (median age 4.5 years) were analysed. There 
was no difference between the two groups for length 
of stay in hospital (median 6 days for both groups). 
PEF increased in the active treatment group from a 
median of 31% predicted on admission to 71% at 
discharge (P<O.OOOl); corresponding figures for the 
placebo group were 32% and 73%, respectively 
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Fig, I Change in PEF (a) and diurnal variation in PEF (b) 
during admission and following discharge from hospital 
with abrupt cessation of oral prednisolone at the time of 
discharge (+) and tailing-off of prednisolone after discharge 
cm). 
(P<O.OOOl). There was no difference between the two 
groups in the median values of FEV,, FVC and TLC 
at the time of discharge from hospital. There was no 
further change in PEF [Fig. l(a)], PEF amplitude % 
mean [Fig. l(b)], FEV, [Fig. 2(a)], FVC [Fig. 2(b)] or 
TLC (Fig. 3) at 14 days or 28 days after discharge 
and there was no difference between the two groups 
at these times. 
Discussion 
We have studied a selected group of asthmatic 
patients who responded quickly following an 
exacerbation of asthma with a standardized dose of 
40 mg prednisolone. There was no difference in lung 
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Fig. 2 Change in FVC (a) and FEV, (b) during admission 
and following discharge from hospital with abrupt cessation 
of oral prednisolone at the time of discharge (+) and 
tailing-off of prednisolone after discharge ( n ), 
function over the 4 weeks following discharge 
from hospital between the patients who stopped 
prednisolone abruptly and those who ‘tailed off’ the 
prednisolone gradually over 2 weeks. 
It is important to note that patients in our study 
were continued on 40 mg prednisolone until they 
achieved a satisfactory and stable PEF for 48 h 
before they were discharged from hospital with a 
gradual reduction or sudden cessation of predniso- 
lone treatment. It is likely that premature cessation of 
systemic corticosteroid therapy would result in a 
worsening of asthma. All our patients were continued 
on inhaled corticosteroid treatment and it is likely 
that this prevented the deterioration in lung function 
in some patients. 
British Thoracic Society Guidelines recommend 
that all patients admitted to hospital with acute 
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Fig. 3 Change in TLC during admission and following 
discharge from hospital with abrupt cessation or oral pred- 
nisolone at the time of discharge (+) and tailing-off of 
prednisolone after discharge ( n ). 
severe asthma should continue prednisolone for l-3 
weeks following discharge from hospital. This is 
justified on the grounds that it may take up to 2 
weeks for maximum improvement in pulmonary 
function to be achieved (1). There is at present no 
agreement on the length of corticosteroid treatment 
required. The practice of a gradual reduction in 
systemic corticosteroid treatment was introduced in 
the mid 1950s (7). This was aimed at preventing a 
rebound worsening of asthma and allowing a recov- 
ery of the hypothalamic-pituitary-adrenal axis fol- 
lowing corticosteroid induced suppression. Recovery 
in adrenal function following short courses of pred- 
nisolone up to 3 weeks appears to be rapid (8) 
however and does not justify a gradual ‘tailing off’ of 
oral corticosteroid treatment. Our study does not 
show a rebound worsening in asthma following sud- 
den cessation of prednisolone. There does not there- 
fore appear to be a need to reduce prednisolone 
gradually following recovery from an acute exacer- 
bation of asthma provided prednisolone treatment 
is continued until a satisfactory and stable PEF is 
achieved. 
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